TACSTD2 and esophageal squamous cell carcinoma: Therefore, the 4 human ESCC cell lines were selected for experiments to test the in vitro efficacy of IMMU (FDA-approved ADC targeted TROP2) and IACS (OXPHOS inhibitor).